University of Florida
Gainesville, Florida, 32608, United States
Location status: Recruiting
NCT Number: NCT05814055
This study will evaluate the compliance with a daily kava regimen among active smokers who have an intention to quit smoking. This study will also investigate whether kava use can facilitate tobacco cessation, reduce stress, and improve sleep.
Interested in participating?
Request Info21 year–75 year
All sexes
Interventional
Phase 2
Gainesville, Florida, 32608, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants on this arm will take one placebo capsule orally three times daily for 4 weeks.
Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 4 weeks.
Time frame: 4 weeks
Evaluate subject compliance with the kava intervention, as measured by participant reported number of missed doses
Time frame: 4 weeks
Evaluate subject compliance with the kava intervention, as measured by detection of dihydromethysticin in participant urine by urine testing
Time frame: 12 weeks
Examine whether kava has the potential to help facilitate tobacco cessation, as measured by participant reported number of cigarettes smoked
Time frame: 12 weeks
Examine whether kava has the potential to help facilitate tobacco cessation, as measured by the Fagerström Test for Nicotine Dependence (FTND)
Time frame: 12 weeks
Examine whether kava has the potential to help facilitate tobacco cessation, as measured by the Modified Cigarette Evaluation Questionnaire (mCEQ)
Time frame: 12 weeks
Examine whether kava has the potential to help facilitate tobacco cessation, as measured by the Brief Questionnaire on Smoking Urges (QSU-Brief)
Time frame: 12 weeks
Examine whether kava has the potential to help facilitate tobacco cessation, as measured by urinary total nicotine equivalents
Time frame: 12 weeks
Examine whether kava has the potential to reduce stress, as measured by the Perceived Stress Scale (PSS). The Perceived Stress Scale consists of 10 items that are each scored on a scale of 0-4. The maximum possible score for this instrument is 40 and the minimum score is 0. A higher score indicates greater perceived stress.
Time frame: 12 weeks
Examine whether kava has the potential to reduce stress, as measured by plasma PRKACA
Time frame: 12 weeks
Examine whether kava has the potential to reduce stress, as measured by plasma cortisol
Time frame: 12 weeks
Examine whether kava has the potential to reduce stress, as measured by urinary TCE
Time frame: 12 weeks
Examine whether kava has the potential to reduce stress, as measured by total cortisol equivalents
Time frame: 12 weeks
Examine whether kava has the potential to improve sleep, as measured by the Insomnia Severity Scale. The Insomnia Severity Scale instrument consists of 7 items that are each scored on a scale of 0-4. The maximum possible score for this instrument is 28 and the minimum score is 0. A higher score indicates more severe insomnia.
Time frame: 12 weeks
Examine whether kava has the potential to improve sleep, as measured by the Pittsburgh Sleep Quality Index (PSQI)
Time frame: 12 weeks
Examine whether kava has the potential to improve sleep, as measured by urinary 6-hydroxymelatonin
Time frame: 12 weeks
Examine whether kava has the potential to improve sleep, as measured by urinary N-acetyl serotonin
Time frame: 12 weeks
Examine whether kava has the potential to improve sleep, as measured by urinary NAS
Contact information is provided by the study sponsor or research team.
Chengguo Dr. Xing
CONTACT
Ramzi G Dr. Salloum
CONTACT
University of Florida
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06346028
Behavior, Chemically-Induced Disorders
Toronto, Ontario, Canada
View Trial DetailsNCT07501624
AIDS, Acquired Immunodeficiency Syndrome
Charleston, South Carolina, United States
View Trial DetailsNCT06910566
Behavior, Chemically-Induced Disorders
Lille, France
View Trial DetailsNCT05952401
Behavior, Chemically-Induced Disorders
St Louis, Missouri, United States
View Trial Details